Avadel Pharmaceuticals PLC (AVDL)vsTeva Pharma Industries Ltd ADR (TEVA)
AVDL
Avadel Pharmaceuticals PLC
$21.64
0.00%
HEALTHCARE · Cap: $2.12B
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 6844% more annual revenue ($17.26B vs $248.52M). TEVA leads profitability with a 8.2% profit margin vs -0.1%. AVDL appears more attractively valued with a PEG of 0.07. TEVA earns a higher WallStSmart Score of 73/100 (B).
AVDL
Hold41
out of 100
Grade: D
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVDL.
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Revenue surging 54.9% year-over-year
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
0.0% earnings growth
Operating margin of 2.5%
Weak financial health signals
Trading at 21.4x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AVDL
The strongest argument for AVDL centers on PEG Ratio, Revenue Growth. Revenue growth of 54.9% demonstrates continued momentum. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : AVDL
The primary concerns for AVDL are EPS Growth, Operating Margin, Piotroski F-Score.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
AVDL profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
AVDL carries more volatility with a beta of 1.63 — expect wider price swings.
AVDL is growing revenue faster at 54.9% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 41/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avadel Pharmaceuticals PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?